Open access
Open access
Powered by Google Translator Translator

Covid-19

WHO: Vaccine inequity undermining global economic recovery.

23 Jul, 2021 | 10:53h | UTC

News release: Vaccine inequity undermining global economic recovery – World Health Organization

Dashboard: Global Dashboard for Vaccine Equity

Commentaries: Urgent need for COVID-19 vaccine equity – University of Oxford AND COVID-19 Vaccine Inequity Undermines Global Economic Recovery  – Health Policy Watch

 

Commentary on Twitter (thread – click for more)

 


Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

23 Jul, 2021 | 10:51h | UTC

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet

Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 


Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

23 Jul, 2021 | 10:49h | UTC

SARS-CoV-2 Human Challenge Studies — Establishing the Model during an Evolving Pandemic – New England Journal of Medicine

Related: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject) AND Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

 


Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.

23 Jul, 2021 | 10:47h | UTC

Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients – Intensive Care Medicine

 


How the Delta variant achieves its ultrafast spread – “Viral load is roughly 1,000 times higher in people infected with the Delta variant than those infected with the original coronavirus strain, according to a study in China”.

23 Jul, 2021 | 10:46h | UTC

How the Delta variant achieves its ultrafast spread – Nature

Original study: Study shows the viral loads in the Delta infections are ~1000 times higher than those in the earlier strain infections on the day when viruses are firstly detected.

 


What are the Delta, Gamma, Beta and Alpha Covid variants?

23 Jul, 2021 | 10:45h | UTC

What are the Delta, Gamma, Beta and Alpha Covid variants? – BBC

Related: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. AND WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.

 


The Lambda variant: is it more infectious, and can it escape vaccines? A virologist explains.

23 Jul, 2021 | 10:43h | UTC

The Lambda variant: is it more infectious, and can it escape vaccines? A virologist explains – The Conversation

Related: Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch

 


Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

22 Jul, 2021 | 11:16h | UTC

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant – New England Journal of Medicine

Commentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider

Related: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. AND Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AND Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

 

Commentary on Twitter

 


COVID-19 antibodies persist at least nine months after infection – “98.8 percent of people infected in February/March showed detectable levels of antibodies in November”.

22 Jul, 2021 | 11:14h | UTC

News release: COVID-19 antibodies persist at least nine months after infection – Imperial College London

Original study: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications

 


RCT: Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 – safe, but no statistically significant risk reduction in organ dysfunction or death.

22 Jul, 2021 | 11:08h | UTC

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Diabetes & Endocrinology

Commentary: Dapagliflozin in patients with COVID-19: truth or dare – The Lancet Diabetes & Endocrinology

 


Should children get COVID vaccines? What the science says.

22 Jul, 2021 | 11:06h | UTC

Should children get COVID vaccines? What the science says – Nature

 


Analysis finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis.

22 Jul, 2021 | 11:05h | UTC

News release: Study finds benefits of COVID-19 vaccination outweigh risks of rare cases of myocarditis – American Heart Association

Original study: Myocarditis with COVID-19 mRNA Vaccines – Circulation

Commentary: Myocarditis and COVID-19 Vaccines: New Review Tackles Knowns, Unknowns – TCTMD

 

Commentary on Twitter

 


Opinion | The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation.

22 Jul, 2021 | 10:57h | UTC

The benefits of a COVID vaccine far outweigh the small risk of treatable heart inflammation – The Conversation

 


Opinion | Kids aren’t just littler adults – here’s why they need their own clinical trials for a COVID-19 vaccine.

22 Jul, 2021 | 10:55h | UTC

Kids aren’t just littler adults – here’s why they need their own clinical trials for a COVID-19 vaccine – The Conversation

 


More than 1.5 million children lost a primary or secondary caregiver due to the COVID-19 pandemic.

21 Jul, 2021 | 10:52h | UTC

News release: More than 1.5 million children lost a primary or secondary caregiver due to the COVID-19 pandemic – NIH News Releases

Original study: Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study – The Lancet

Invited commentary: Answering the call to support youth orphaned by COVID-19 – The Lancet

Related: Covid-19 Has Created Thousands Of Newly Single Parents And Orphans

 

Commentary on Twitter (thread – click for more)

 


Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.

21 Jul, 2021 | 10:51h | UTC

Exploring the Gap Between Excess Mortality and COVID-19 Deaths in 67 Countries – JAMA Network Open

 


Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.

21 Jul, 2021 | 10:49h | UTC

Three New Estimates of India’s All-Cause Excess Mortality during the COVID-19 Pandemic – Center for Global Development

Commentaries: India’s pandemic death toll could be in the millions – Associated Press AND Covid-19: India excess deaths cross four million, says study – BBC AND India’s true pandemic death toll is likely to be well over 3 million, a new study finds. – The New York Times AND India’s excess deaths during Covid ‘could be 10 times official toll’ – The Guardian

 

Commentary on Twitter

 


Perspective | Potential COVID-19 endgame scenarios: eradication, elimination, cohabitation, or conflagration?

21 Jul, 2021 | 10:48h | UTC

Potential COVID-19 Endgame Scenarios: Eradication, Elimination, Cohabitation, or Conflagration? – JAMA

 


Is the cure really worse than the disease? The health impacts of lockdowns during COVID-19 – “While there are certainly costs to be expected from intervening against COVID-19—every decision has a cost, after all—the counterfactual of an unmitigated epidemic makes these restrictions far less damaging than some have suggested”.

21 Jul, 2021 | 10:46h | UTC

Is the cure really worse than the disease? The health impacts of lockdowns during COVID-19 – BMJ Global Health

Commentaries: Expert reaction to a narrative review looking at the health impacts of lockdowns – Science Media Centre AND Lockdowns do not harm health more than Covid, say researchers – The Guardian

 

Commentary on Twitter (thread – click for more)

 


Cohort study: Sickle cell disorders and severe COVID-19 outcomes – “Our analysis estimated a 4-fold increased risk for COVID-19–related hospitalization and a 2.6-fold increased risk for COVID-19–related death for sickle cell disease”.

21 Jul, 2021 | 10:44h | UTC

Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine

 


WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

20 Jul, 2021 | 10:29h | UTC

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) – World Health Organization

Related Guidance: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.” AND ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

 


WHO and UNICEF warn of a decline in vaccinations during COVID-19.

20 Jul, 2021 | 10:27h | UTC

WHO and UNICEF warn of a decline in vaccinations during COVID-19 – World Health Organization

See also: COVID-19 pandemic leads to major backsliding on childhood vaccinations, new WHO, UNICEF data shows – World Health Organization

Related: Millions of children worldwide missed routine vaccinations during the pandemic, study suggests.

 


WHO warns that HIV infection increases risk of severe and critical COVID-19.

20 Jul, 2021 | 10:24h | UTC

News release: WHO warns that HIV infection increases risk of severe and critical COVID-19 – World Health Organization

Report: WHO report on clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with SARS-CoV-2 infection

Related: M-A: Epidemiology and outcomes of COVID-19 in HIV-infected individuals – HIV is a significant risk factor for acquiring SARS-CoV-2 infection and is associated with a higher risk of mortality.

 

Commentary on Twitter (thread – click for more)

 


International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

20 Jul, 2021 | 10:21h | UTC

Ischemic and Hemorrhagic Stroke Among Critically Ill Patients With Coronavirus Disease 2019: An International Multicenter Coronavirus Disease 2019 Critical Care Consortium Study – Critical Care Medicine

Related: SARS-CoV-2 and Stroke Characteristics – higher rate of large vessel occlusions and stroke in young patients AND Case series of 18 male adults aged 50 years or younger with acute ischemic stroke during the convalescent phase of asymptomatic Covid-19 AND Case-control study: COVID-19-associated stroke is associated with worse outcomes and increased mortality AND Pictorial essay: Neurological emergencies associated with COVID-19: stroke and beyond AND Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke AND Risk of Ischemic Stroke in Patients with COVID-19 vs. Patients with Influenza

 


Editorial: Defining covid-19 elimination.

20 Jul, 2021 | 10:20h | UTC

Defining covid-19 elimination – The BMJ

 


Stay Updated in Your Specialty

No spam, just news.